BioVie Inc. Announces Pricing of $12 Million Public Offering
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic...
What is the anticipated impact of this capital raise on BioVie's cash runway and timeline to key clinical trial milestones?
Are there any covenants or redemption rights associated with the pre‑funded warrants that could affect future capital structure?
Will the increased float improve liquidity and bid‑ask spreads for BIVI, or could it lead to heightened volatility?
about 1 month ago